$JCTC

Thursday’s insider activity: Notable buys and strategic sales By Investing.com

Investing.com reports US insider trades disclosed Thursday. Buys: JCTC ($25,871; 11,009 shares at $2.35), BGDE ($16.7M Series D at $1,000), HDSN (~764,202 shares for ~$4.48M), BOLD (~$268,880), and COLB ($22,477). Sells: CRWV CEO sold ~$37.7M; EWTX CSO sold ~$7.88M; ALAB director sold ~$5.62M.

Original reporting
Published Jul 3, 2026, 1:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 3, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$JCTC
Bullish
medium confidence
Mentioned
$JCTC · $BGDE · $HDSN · $BOLD · $COLB · $CRWV
Relevance
4/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$JCTCBullishLow
01

Why it matters

For traders, the most actionable signal is the magnitude and timing of top-executive selling in CRWV; other names are mostly sentiment/positioning inputs without new operational catalysts.

02

Market read

Insider flow data can move short-term sentiment, but this article lacks earnings/guidance/contract/regulatory triggers, limiting tradability to flow-driven positioning.

03

What to watch

The article omits key Form 4 details that drive interpretation (e.g., remaining shares, total ownership changes, whether buys/sells are part of broader financing/hedging, and the conversion/dilution terms for BGDE’s preferred investment).

Relevance 4/10Novelty 4/10Timing: insider transactions disclosed for trades dated June 30–July 2, 2026

Background

Roundup of notable US insider buying/selling disclosed on Thursday, with transaction dates, share counts, prices, and (for some) Rule 10b5-1 plan context.

Company-level read

Ticker impact

$JCTCBullishMedium confidence
Context

Jewett Cameron Trading Co coordinated purchases by 10% owners totaled $25,871 at $2.35 on July 1, 2026.

Expected impact

Near-term support possible, but likely limited follow-through without additional fundamentals.

Evidence & confidence

The disclosure is a fresh Form 4-style insider buy, yet it’s not tied to guidance, contracts, or earnings—so impact is typically sentiment-driven.

$BGDEBullishMedium confidence
Context

Big Digital Energy received a $16.7M Series D convertible preferred investment at $1,000 per share on June 30, 2026.

Expected impact

Potential relief rally or reduced downside risk, especially if terms are viewed as supportive.

Evidence & confidence

The article provides size, date, and investor identity, but lacks key terms (conversion, dilution, covenants) that determine true valuation impact.

$HDSNBullishMedium confidence
Context

Hartree Partners, a 10% owner, bought 764,202 shares of Hudson Technologies over June 30–July 2 at $5.6785–$5.9683.

Expected impact

Moderately bullish bias over days/weeks if market treats it as a signal rather than routine tax/rollover activity.

Evidence & confidence

The scale and repeated buys are meaningful, but the article doesn’t clarify whether this is part of a broader strategy or financing.

$BOLDBullishLow confidence
Context

Boundless Bio saw 10% owners buy ~$268,880 of stock at $2.49–$2.54 between June 30 and July 2.

Expected impact

Limited upside unless accompanied by new guidance/clinical or financing news.

Evidence & confidence

The article provides transaction details but no new company-specific development beyond the buy and valuation commentary.

$COLBBullishLow confidence
Context

Columbia Banking System executive purchased $22,477 of shares via an ESPP on June 30, 2026 at $25.37.

Expected impact

Minimal impact; more relevant as a minor sentiment datapoint than a trading trigger.

Evidence & confidence

ESPP purchases are often formulaic and the article doesn’t indicate a change in outlook or material corporate action.

$CRWVBearishHigh confidence
Context

CoreWeave CEO/president sold ~$37.7M of Class A stock on June 30, 2026 at $94.6561–$99.5359 under a Rule 10b5-1 plan.

Expected impact

Bearish near-term bias; could cap rallies until buyers/earnings clarify fundamentals.

Evidence & confidence

The article cites substantial dollar value, specific dates/prices, and 10b5-1 mechanics—making it a concrete, time-relevant flow signal.

$EWTXBearishMedium confidence
Context

Edgewise Therapeutics’ CSO sold 200,000 shares for ~$7.88M on July 1, 2026 at $38.77–$40.905.

Expected impact

Short-term downside/mean-reversion risk if the market reads it as reduced conviction.

Evidence & confidence

The transaction is large and dated, but the article notes it followed option exercises—so part of the sale may be mechanical.

$ALABBearishLow confidence
Context

Astera Labs director sold 12,499 shares on July 1, 2026 for $5.62M at $450.00 under a Rule 10b5-1 plan.

Expected impact

Limited impact unless paired with other negative catalysts; may slightly weigh on momentum.

Evidence & confidence

The article provides the sale size and plan type, but lacks context on whether it’s routine or tied to diversification/compensation.

Market effects

No single sector catalyst; the piece is a cross-section of insider flows across tech/biotech/financials.

US-focused insider activity; could marginally affect sentiment in high-beta growth names.

Limited—no cross-border deal/regulatory/commodity linkage beyond general market context.

Counterpoint

Insider selling is often pre-planned (10b5-1) and can reflect tax/compensation mechanics rather than bearish fundamentals; insider buys can also be diversification.

Key entities

  • CoreWeave, Inc.

    CEO/president sold ~$37.7M of Class A stock on June 30, 2026 under a Rule 10b5-1 plan.

  • Big Digital Energy, Inc.

    Received a $16.7M Series D convertible preferred investment on June 30, 2026.

Related articles

$ALABMed

Astera Labs Beat And Guided Higher, Then Fell Because The Rally Came First

Astera Labs (ALAB) reported record fiscal Q2 2026 results, with revenue of $392.4M up 104% year over year, and issued fiscal Q3 2026 guidance of $540M to $560M, above expectations. The stock later fell about 12% after four prior up sessions. The article attributes the shift to product mix, with PCIe 6 and Scorpio switch family ramping, and a non-GAAP gross margin guide down to about 72% from 74%.

$HDSNMed

Hudson Technologies Q2 Earnings Call Highlights

Hudson Technologies (NASDAQ:HDSN) reported Q2 revenue of $78.3 million, up 8% year over year, with sales volume up 12% but average refrigerant selling price down 6%. Gross margin fell to 26% from 31% a year earlier. The company revised its FY2026 gross-margin target to the low-to-mid-20% range and said the Defense Logistics Agency re-awarded a five-year $210 million contract.

$EWTXMedAI 8/10

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Edgewise Therapeutics (Nasdaq: EWTX) reported Q2 2026 results and said its EDG-7500 12-week Phase 2 CIRRUS-HCM trial showed positive top-line data in obstructive and nonobstructive HCM, with Phase 3 planned for Q4 2026. In July 2026, it completed selling sevasemten and its muscular dystrophy business to Servier for $1.55B upfront plus up to $1.1B milestones. Q2 cash was about $460.7M; net loss was $57.3M.

$EWTXMed

Edgewise Therapeutics, Inc. (EWTX): Results of Operations and Financial Condition

Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621653d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2026 Financial Results – Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardio